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Abstract
Background: The potential benefit of adding recombinant human luteinizing
hormone (r-hLH) to recombinant human follicle-stimulating hormone (r-hFSH)
during ovarian stimulation is a subject of debate, although there is evidence that it
may benefit certain subpopulations, e.g. poor responders.Methods: A systematic
review and a meta-analysis were performed. Three databases (MEDLINE,
Embase and CENTRAL) were searched (from 1990 to 2011). Prospective,
parallel-, comparative-group randomized controlled trials (RCTs) in women aged
18-45 years undergoing in vitro fertilization, intracytoplasmic sperm injection or
both, treated with gonadotrophin-releasing hormone analogues and r-hFSH plus
r-hLH or r-hFSH alone were included. The co-primary endpoints were number of
oocytes retrieved and clinical pregnancy rate. Analyses were conducted for the
overall population and for prospectively identified patient subgroups, including
patients with poor ovarian response (POR).Results: In total, 40 RCTs (6...
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The aim of this systematic review and meta-analysis was to assess whether the addition of recombinant luteinizing
hormone (LH) increases live birth rate, among patients treated with follicle stimulating hormone (FSH) and gonado-
trophin-releasing hormone (GnRH) analogues for in vitro fertilization (IVF). Eligible studies were randomized con-
trolled trials (RCTs) answering the research question that contained sufficient information to allow ascertainment
of whether randomization was true and whether equality was present between the groups compared, regarding base-
line demographic characteristics, gonadotrophin stimulation protocol, number of embryos transferred and luteal
phase support administered. A literature search identified seven RCTs (701 patients) that provided the information
of interest, among which five reported agonist and two antagonist cycles. The reported outcome measure, clinical
pregnancy, was converted to live birth using published data in one study. No significant difference in the probability
of live birth was present with or without rLH addition to FSH (odds ratio [OR]: 0.92, 95% confidence interval (CI):
0.65–1.31; P5 0.65). This finding remained stable in subgroup analyses that ordered the studies by dose of rLH
added, the type of analogue used to inhibit premature LH surge, the time rLH was added during the follicular
phase, the age of patients analysed, the presence of allocation concealment and by the way the information on live
birth was retrieved. In conclusion, the available evidence does not support the hypothesis that the addition of recom-
binant LH increases the live birth rate in patients treated with FSH and GnRH analogues for IVF.
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Introduction
The role of endogenous LH levels during ovarian stimulation has
attracted a lot of attention since the early in-vitro fertilization
(IVF) years (Stanger and Yovich, 1985; Howles et al., 1987;
Thomas et al., 1989). At present, available evidence suggests
that among women with normal ovulation or World Health Organ-
ization (WHO) II oligo-anovulation, low endogenous LH levels
during ovarian stimulation for IVF using gonadotrophin-releasing
hormone (GnRH) analogues are not associated with a decreased
probability of ongoing pregnancy beyond 12 weeks (Kolibianakis
et al., 2006).
On the basis of these data, an adverse role of low endogenous
LH levels on the probability of pregnancy cannot serve as a ration-
ale for LH supplementation in ovarian stimulation for IVF.
However, it cannot be excluded that LH supplementation during
the follicular phase might be beneficial for pregnancy achieve-
ment, independently of any effect of endogenous LH levels.
Several studies have so far evaluated the addition of recombinant
LH (rLH) to FSH in ovarian stimulation for IVF (Table 1). Due
to sample size restrictions, however, these individual studies are
usually not conclusive as regards the effect of LH supplementation
on pregnancy likelihood.
The purpose of the current systematic review and meta-analysis
was to summarize the available published evidence regarding the
role of rLH addition in ovarian stimulation for IVF by answering
the following clinical question: among patients treated with FSH
and GnRH analogues for IVF, does the addition of rLH increase
live birth rate?
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Materials and Methods
Identification of studies
In April 2006, a computerized literature search was performed on the
bibliographic databases EMBASE, MEDLINE and CENTRAL
without time limitations. Additionally, references of retrieved articles
were hand-searched. The search strategy aimed at identifying random-
ized controlled trials (RCTs) on the basis of the following clinical
question: among patients treated with FSH and GnRH analogues is
the addition of rLH associated with the probability of live birth?
Search terms used were ‘luveris’, ‘lutropin alfa’, ‘recombinant LH’
and ‘recombinant luteinizing hormone’. The search was limited to
RCTs in humans. Meeting proceedings were not considered, since
unpublished studies cannot be adequately evaluated for their design
and quality. Moreover, it has been shown that although there is a
considerable publication deficit in reproductive medicine for RCTs,
there is no concomitant publication bias (Evers, 2000).
Selection of studies
Criteria for inclusion/exclusion of studies were established prior to
the literature search. Eligible studies were RCTs answering the
research question that contained sufficient information to allow ascer-
tainment of whether randomization was true and whether equality was
present between the groups compared, regarding baseline demo-
graphic characteristics, gonadotrophin stimulation protocol, number
of embryos transferred and luteal phase support (LPS) administered.
An effort was made to contact all authors or sponsors of studies to
retrieve missing or additional information.
Studies were excluded if no down-regulation was used for ovarian
stimulation for IVF or if the gonadotrophin used for ovarian stimu-
lation contained LH. Language of publication or number of patients
analysed was not amongst the exclusion criteria.
Studies identified
Literature search yielded 74 studies that were potentially able to
answer the research question. Further evaluation based on study
titles and abstracts and/or assessment of full manuscripts resulted in
15 studies that evaluated the role of LH addition on the probability
of live birth. Thirty-seven studies were excluded after screening the
titles and a further 22 were excluded after screening the abstracts.
The question of interest was answered in seven of these studies
(Tables 1 and 2). Eight studies were excluded because a
quasi-randomization was used for patient allocation (n ¼ 2), because
randomization method was unclear (n ¼ 1), because, besides rLH
addition, the dose of FSH was also modified at the same time (n ¼
3) or because problems occurred during the study period (n ¼ 2)
(Table 3).
Data extraction
The following data were recorded from each of the studies in parallel
by two of the authors (L.K., E.M.K.): demographic (type of study,
country of origin and period of enrolment), methodological (ran-
domization method, allocation concealment, randomization ratio,
whether sample size calculation was performed), procedural
(whether financial support was declared, number of patients included,
Table 1: Characteristics of the RCTs included in the meta-analysis
Study, country of
origin (number of
centres)
Journal Study period Randomization
method; allocation
concealment
Sample size
calculation
Number of
participants
Financial support
by pharmaceutical
company
Sills et al. (1999),
USA (single centre)
Hum Reprod February 1996–
November 1996
Randomization table;
no
No ITT population:
30; hpFSH: 17;
hpFSH þ rLH: 13
Yes
Balasch et al. (2001),
Spain (single centre)
J Assist Reprod Genet Not stated Computer-generated
randomization table;
yes (sealed
envelopes)
No ITT population:
30; rFSH: 14;
rFSH þ rLH: 16
Yes
Humaidan et al.
(2004), Denmark
(single centre)
Reprod Biomed
Online
November 2001–
October 2002
Computer-generated
randomization table;
yes (sealed
envelopes)
Yes, for pregnancy
rate
ITT population:
231; rFSH: 115;
rFSH þ rLH: 116
Not stated
Sauer et al. (2004),
USA (mutlicentre)
Reprod Biomed
Online
Not stated Computer-generated
randomization table;
no
No ITT population:
73; rFSH: 24;
rFSH þ rLH: 25
Yes
Griesinger et al.
(2005), Germany
(single centre)
Hum Reprod June 2003–May 2004 Computer-generated
randomization table;
yes (sealed
envelopes)
Yes, for the duration
of gonadotrophin
treatment (days)
ITT population:
127; rFSH: 65;
rFSH þ rLH: 62
Not stated
Tarlatzis et al.
(2006), multinational
(multicentre)
Hum Reprod Not stated Computer-generated
randomization table;
yes (sealed
envelopes)
Yes, for metaphase II
oocytes retrieved
ITT population:
114; rFSH: 59;
rFSH þ rLH: 55
Yes
Fabregues et al.
(2006), Spain
(single centre)
Fertil Steril November 2003–
September 2004
Computer-generated
randomization table;
yes (sealed
envelopes)
Yes, for pregnancy
rate
ITT population:
120; rFSH: 60;
rFSH þ rLH: 60
Not stated
hpFSH: highly purified follicle stimulating hormone, rFSH: recombinant follicle stimulating hormone, rLH: recombinant luteinizing hormone, ITT: intention to
treat.
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type and protocol of ovarian stimulation, type of gonadotrophin admi-
nistered, criteria for human chorionic gonadotrophin (hCG) adminis-
tration and dose of hCG, type of fertilization, day of embryo
transfer and type of luteal support administered) and outcome data
(live birth rate, duration of stimulation, dose of FSH required, fertili-
zation rate, number of cumulus–oocyte complexes (COCs) retrieved,
estradiol (E2) and progesterone level on the day of hCG adminis-
tration). Where standard deviation (SD) was not reported by the
authors, it was calculated from the standard error of the mean
(SEM). The values reported as SDs in the study by Fabregues et al.
(2006) were considered as SEMs following communication with the
authors. Any disagreement between the persons responsible for data
extraction was solved by discussion.
Where live birth was not reported in a study that fulfilled the
inclusion criteria, an effort was made to contact the corresponding
authors to retrieve the missing information. If this was not possible,
the reported outcome measure, clinical pregnancy, was converted to
live birth using published data (84% probability of live birth after
Table 2: Characteristics of the RCTs included in the meta-analysis
Study GnRH analogue
protocol;
analogue (dose)
FSH type in
control group;
starting dose;
dose adjustments
Gonadotrophin
treatment regimen in
the study group
hCG Criteria for hCG
administration
Fertilization ET day LPS
Sills et al.
(1999)
Long luteal;
leuprorelin (1 or
0.5 mg/day, s.c.)
hpFSH; 150–
450 IU; yes: step
down protocol
hpFSH protocol as in
control group, plus
75 IU rhLH daily
from initiation of
stimulation (no rLH
dose adjustments)
Up to
10 000 IU
hCG
At least two
follicles 17 mm
IVF or ICSI Day 3 Progesterone
Balasch et al.
(2001)
Long luteal;
leuprorelin (1 or
0.5 mg/day, s.c.)
rFSH; 450 IU;
yes: step-down
protocol
rFSH protocol as in
control group, plus
75 IU rhLH daily
from initiation of
stimulation (no rLH
dose adjustments)
5000 IU
hCG
Consistent E2 rise
observed in the
presence of 2
follicles .18 mm
IVF or ICSI Not stated hCG
Humaidan
et al. (2004)
Long luteal;
buserelin (0.5 or
0.2 mg/day, s.c.)
rFSH; 150–
300 IU; yes, from
day 8 onwards if
necessary
rFSH protocol as in
control group, plus
rLH from day 8
onwards (rFSH and
rLH given in 2 : 1
ratio)
10 000 IU
hCG
At least three
follicles 17 mm
IVF or ICSI Day 2, 3 or
5
Progesterone
Sauer et al.
(2004)
(Pretreatment with
OCP-single dose
antagonist;
cetrorelix (3 mg
s.c.)
rFSH; 225 IU;
yes, from day 6
onwards if
necessary
rFSH protocol as in
control group, plus
150 IU rLH from day
of cetrorelix initiation
onwards (no rLH
dose adjustments)
250 mg
rhCG
At least one
follicle 18 mm,
at least two other
follicles 16 mm
and serum E2
150 pg/ml per
mature follicle
ICSI Not stated Progesterone
Griesinger
et al. (2005)
Cetrorelix starting
on stimulation day
6 (0.25 mg/day)
rFSH; 150 IU;
yes, from day 6
onwards if
necessary
rFSH protocol as in
control group, plus
75 IU rLH. rLH dose
adjustments from day
6 according to rFSH
adjustment
250 mg
rhCG
Three follicles
18 mm
IVF or ICSI Day 2 Progesterone
and hCG
Tarlatzis et al.
(2006)
Long follicular;
buserelin
(0.2 mg/day, s.c.)
rFSH; 150 IU;
yes, from day 6
onwards if
necessary
rFSH protocol as in
control group, plus
75 IU rLH when
leading follicle
reached 14 mm (no
rLH dose
adjustments)
10 000 IU
hCG
At least two
follicles .17 mm
IVF or ICSI Day 2 Progesterone
Fabregues
et al. (2006)
Long luteal;
triptorelin (0.1 or
0.05 mg/day, s.c.)
rFSH; 450 IU;
yes, step down
protocol
rFSH protocol as in
control group, plus
150 IU rhLH from
day 6 onwards (no
rLH dose
adjustments)
250 mg
hCG
2 follicles
18 mm, with
4 follicles
14 mm in
association with
consistent rise in
E2
IVF or ICSI Day 2 or 3 Progesterone
OCP: oral contraceptive pill, rFSH: recombinant follicle stimulating hormone, rLH: recombinant luteinizing hormone, hCG: human chorionic gonadotrophin,
IVF: in vitro fertilization, ICSI: intra cytoplesmic sperm injection, rhCG: recombinant hCG, s.c.: subcutaneous, hpFSH: highly purified follicle stimulating
hormone, LPS: luteal phase support, GnRH: gonodotrophin releasing hormone, E2: estradiol, ET: embryo transfer.
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confirmation of clinical pregnancy with a living fetus at the 7th week
of gestation) (Arce et al., 2005). This live birth equivalent was calcu-
lated in one study: Sauer et al. (2004). In addition, information was
sought from the corresponding authors regarding live birth in patients
who were randomized but did not start treatment within the study
period. Where this information was not available (Griesinger et al.,
2005), these patients were considered as not pregnant (n ¼ 1).
Outcome variables
The primary outcome variable was live birth rate per randomized
patient (described as delivery rate in the study by Sills et al., 1999).
Secondary outcome variables were clinical pregnancy rate, gonado-
trophin consumption (per cycle); duration of stimulation (per cycle),
E2 level on the day of hCG, progesterone level on the day of hCG,
number of COCs retrieved (per cycle), fertilization rate (per cycle)
and number of 2PN oocytes (per cycle).
Quantitative data synthesis
Study features and results were assembled in tabular form, and a
formal meta-analysis was performed. The dichotomous data results
for each study were expressed as an odds ratio (OR) with 95% confi-
dence intervals (CI). These results were combined for meta-analysis
with Comprehensive Meta-analysis software (Biostat, 14 North
Dean St, Englewood NJ 07631, USA), using the Mantel/Haenszel
method. Live birth rate was calculated for each study per patient
randomized.
When the outcome of interest was of a continuous nature, the differ-
ences were pooled across the studies that provided information on this
outcome variable, resulting in a weighted mean difference (WMD)
with 95% CI.
Study-to-study variation was assessed by using x2 statistic (the
hypothesis tested was that the studies are all drawn from the same
population, i.e. from a population with the same effect size). A fixed
effects model was used where no heterogeneity was present,
whereas in presence of significant heterogeneity a random effects
model was applied.
Subgroup analyses were carried out to check the stability of the
main finding. These analyses ordered the studies according to the
dose of rLH added (75 IU, 150 IU), the type of analogue used to
inhibit premature LH surge (agonist, antagonist), the time rLH was
added during the follicular phase (early follicular phase, mid-follicular
phase), the age of patients analysed (.35 years of age, all ages), the
type of allocation concealment (allocation concealed, concealment
unknown) and according to the way the information on live birth
was retrieved (reported by authors or calculated).
Power analysis
It was calculated that the optimal information size required to reject
the null hypothesis (no difference in live birth rates between the two
treatment groups) was 2504 subjects, assuming a clinically important
difference of 5%, a baseline live birth rate of 25% and using beta 0.2,
alpha 0.05 and a two-tailed hypothesis test.
Results
Seven RCTs fulfilled the inclusion criteria and were included in
the analysis with no disagreement noted between the authors
responsible for study selection. Characteristics of the included
studies are listed in Tables 1 and 2. All analysed studies were pub-
lished between 1999 and 2006. The size of the studies ranged from
29 to 231 patients (median 114), whereas a total of 701 patients
were analysed (FSH only: n ¼ 354, FSH þ rLH: n ¼ 347).
Characteristics of the patients included in these trials are shown
in supplementary Table 1. Two studies were multicentre trials
and all others were single-centre studies. In five studies, patient
allocation was concealed, whereas in the remaining studies con-
cealment of allocation had not been performed or was not
reported.
All the studies were double arm with the exception of the study
by Sauer et al. (2004). In this three-armed study, data were
extracted for analysis from the study arms that provided the infor-
mation with respect to the study research question.
Financial support by a pharmaceutical company was declared in
four out of the seven analysed studies. Two out of the seven studies
reported a power analysis aiming to detect differences in the prob-
ability of pregnancy achievement (Table 1).
To inhibit premature LH surges, agonists were used in five
studies (leuprorelin: n ¼ 2, daily triptorelin: n ¼ 1, buserelin
n ¼ 2) and antagonists in two studies (cetrorelix daily: n ¼ 1,
single dose cetrorelix: n ¼ 1).
For ovarian stimulation, one study used highly purified gonado-
trophins, whereas the remaining studies used recombinant gonado-
trophins. Criteria for triggering final oocyte maturation varied
Table 3: Studies excluded from the meta-analysis
Study, country Main reason for exclusion
Quasi-randomization
Lisi et al. (2002), Italy Allocation of treatment to every third patient
Cedrin-Durnerin et al. (2004), France In centers 2 and 3, patients randomization according to the even or uneven year of the woman’s birth.
Toporcerova et al. (2005), Slovenia Unclear method of randomization
Simultaneous systematic change of FSH at LH initiation
Ferraretti et al. (2004), Italy Increase of FSH dose in addition to rLH initiation in both study arms
Levi-Setti et al. (2005), Italy Decrease of FSH dose in the patients that received rLH
De Placido et al. (2005), Italy Increase of FSH dose at LH initiation in patients that did not receive rLH
Problems during the study period
Lisi et al. (2005), Italy Treatment was not performed according to random allocation in 34 patients
Marrs et al. (2004), USA Significantly different number of embryos were transferred in the two arms of the study
FSH: follicle stimulating hormone, rLH: recombinant luteinizing hormone.
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across studies and were based on follicular data (n ¼ 4) or on a
combination of follicular data and hormonal levels (n ¼ 3). In
three studies, recombinant hCG was used for triggering final
oocyte maturation, whereas the remaining studies used urinary
hCG (10 000 IU in three studies; 5000 IU in one study).
Fertilization methods included both IVF and intracytoplasmic
sperm injection (ICSI). Embryo transfers were performed 2–5
days after oocyte retrieval. Luteal support varied between
studies. The majority of the studies analysed used micronized
progesterone for luteal support.
Live birth rate
The OR for live birth was 0.92 (95% CI: 0.65 to 1.31, P ¼ 0.65;
heterogeneity: P ¼ 0.39, fixed effects model), suggesting that
the probability of live birth was not associated with the addition
of rLH to FSH stimulation (Fig. 1). The rate difference was
1.5% in favour of the FSH only group (95% CI: 27.7 to þ4.85,
P ¼ 0.65; heterogeneity P ¼ 0.32, fixed effects model).
Subgroup analyses of the likelihood of live birth ordered the
studies by dose of rLH added (75 IU, 150 IU), the time rLH was
added during the follicular phase (early follicular, mid-cycle),
the category of analogue used for inhibition of premature LH surge
(agonist, antagonist), the age of the patients analysed (all ages,
.35 years of age), the type of allocation concealment (allocation
concealed, concealment unknown) and the way the information on
live birth was retrieved (reported by authors or calculated). As
illustrated in Figures 2–3 and supplementary Figures 1–4 the
difference in live birth rate between patients treated with FSH
only and those treated with FSH þ rLH remained not significant
in all subgroup analyses. In none of these analyses was heterogen-
eity present, and thus a fixed effects model was used.
In five studies, information was reported both for live birth and
for clinical pregnancy. rLH addition was not associated with either
the probability of clinical pregnancy (OR: 0.85, 95% CI: 0.57–
1.26) or live birth (OR: 0.94, 95% CI: 0.62–1.43) in these studies.
Repeating the analysis with the three excluded quasi-
randomized studies (Lisi et al., 2002; Cedrin-Durnerin et al.,
2005; Toporcerova et al., 2005) sums 1414 patients and does not
materially change the OR for live birth: 1.05 (95% CI: 0.82–
1.36, P ¼ 0.69; heterogeneity: P ¼ 0.50, fixed effects model).
The rate difference was 0.9% in favour of the FSH þ LH group
(95% CI: 23.7 to þ5.5, P ¼ 0.89; heterogeneity P¼ 0.39,
fixed effects model).
The OR for clinical pregnancy in the included studies was 0.86
(95% CI: 0.61–1.20, P ¼ 0.37; heterogeneity: P ¼ 0.35, fixed
Figure 1: OR of live birth rate per randomized patient (heterogeneity: P ¼ 0.39)
Figure 2: OR of live birth rate per randomized patient according to time during the follicular phase that rLH supplementation was initiated (heterogeneity in
different groups: early follicular: P ¼ 0.28; mid-follicular: P ¼ 0.53)
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effects model), suggesting that the probability of clinical preg-
nancy was not associated with the addition of rLH to FSH stimu-
lation. The rate difference was 3.0% in favour of the FSH
only group (95% CI: 29.5 to þ3.5, P ¼ 0.36; heterogeneity
P ¼ 0.34, fixed effects model).
Secondary outcomes
FSH requirement
No significant difference was detected regarding the number of
units of FSH required for ovarian stimulation in patients treated
with FSH þ rLH as compared with those treated with FSH only
(WMD: þ64.44 IU, 95% CI: 251.15 to þ180.02; P ¼ 0.27;
heterogeneity: P ¼ 0.69, fixed effects model). Six studies
offered data for this outcome measure.
Duration of FSH stimulation
The duration of stimulation was not significantly different between
patients treated with FSH þ rLH as compared with those treated
with FSH only (WMD: 20.04 days, 95% CI: 20.31 to þ0.23;
P ¼ 0.77; heterogeneity: P ¼ 0.19; fixed effects model). Seven
studies offered data for this outcome measure.
E2 on the day of hCG administration
Serum E2 was not significantly higher in patients treated with FSH
and rLH as compared with those treated with FSH only (WMD:
þ214.42 pg/ml, 95% CI: 2107.93 to þ536.78 P ¼ 0.019;
heterogeneity: P ¼ 0.04; random effects model). Six studies
offered data for this outcome measure.
Progesterone on the day of hCG administration
Only two studies offered data on the level of serum progesterone
on the day of hCG, which was not significantly different between
patients treated with FSH þ rLH as compared with those treated
with FSH only (WMD: þ0.06 ng/ml, 95% CI: 20.18 to þ0.29
P ¼ 0.63; heterogeneity: P ¼ 0.38; fixed effects model).
COCs retrieved
The number of COCs retrieved was not significantly different
between patients treated with FSH þ rLH as compared with
those treated with FSH only (WMD: 20.57 COCs, 95% CI:
21.46 to þ0.31 P ¼ 0.21; heterogeneity: P ¼ 0.42; fixed effects
model). Seven studies offered data for this outcome measure.
Fertilization rate
Fertilization rate was not significantly different between patients
treated with FSH þ rLH as compared with those treated with
FSH only (WMD: 24.15%, 95% CI: 29.24 to þ0.93 P ¼ 0.11;
heterogeneity: P ¼ 0.24; fixed effects model). This result is
based on the analysis of four studies.
2PN oocytes
The mean number of 2PN oocytes was not significantly different
between patients treated with FSH only and those treated with
FSH and rLH (WMD: þ0.03 2PN oocytes, 95% CI: 20.51 to
þ0.58; P ¼ 0.90; heterogeneity: P ¼ 0.38, fixed effects model).
This result is based on the analysis of five studies.
Discussion
The current systematic review suggests that, among patients
treated with FSH and GnRH analogues for IVF, the addition of
rLH does not increase live birth rate.
It has to be noted that this result should be viewed with caution
since the optimal sample size, required to exclude a clinically sig-
nificant difference, has not yet been reached. Thus the addition of
further RCTs to examine the effect of adding rLH to FSH in
ovarian stimulation for IVF is necessary. Nevertheless, the main
finding of the current meta-analysis is supported by the fact that it
remained stable in all subgroup analyses performed, whereas no sig-
nificant heterogeneity was present between the RCTs analysed.
Interestingly, no trend for a beneficial effect of rLH addition
was present depending on the dose of rLH added to FSH stimu-
lation. As yet, an optimal dose of rLH has not been systematically
assessed in normogonadotropic women (De Placido et al. 2004).
Figure 3: OR of live birth rate per randomized patient according to type of analogue used for ovarian stimulation (heterogeneity in different groups: agonist:
P ¼ 0.18; antagonist: P ¼ 0.84)
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The current evidence suggests that an improvement of the prob-
ability of live birth does not depend on the addition of either 75
or 150 IU of rLH.
In addition, the time that rLH addition was initiated during the fol-
licular phase (early or mid-follicular), did not affect the probability
of live birth. It should be noted that the three studies in which rLH
was started during the early follicular phase did not favour such an
intervention (Fig. 2). Finally, the type of down-regulation (agonist
or antagonist) did not seem to modify the effect of rLH addition to
FSH. The two studies performed using GnRH antagonists for down-
regulation did not favour the addition of rLH to FSH.
In the current meta-analysis, one study out of the seven analysed
reported only clinical pregnancy rates for the population analysed,
whereas information on live birth was not available. In this study,
live birth was calculated using published data (Arce et al. 2005).
This choice was made in order to include this eligible trial in the
current meta-analysis, since otherwise it would have to be ignored.
The assumption for this calculation is that, following confirmation
of clinical pregnancy, the probability of live birth is not different
between patients that received rLH and those that did not receive
rLH in addition to FSH. No published data exist to object to this
assumption, which is further supported by the fact that no significant
effect of rLH addition was detected either for clinical pregnancy or
for live birth in the studies that reported both outcomes.
Regarding secondary outcomes no significant differences were
observed between patients who received rLH and those who did
not, which is in line with the non-significant difference observed
in the probability of live birth.
In conclusion, the current review suggests that, among patients
treated with FSH and GnRH analogues for IVF, the addition of
rLH does not increase live birth rate. Moreover, the available
evidence does not indicate a beneficial effect of rLH addition on
secondary outcome variables.
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